Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation

Journal of Biological Chemistry

Volumn 288, Issue 19, 2013, Pages 13215-13224

  Li, Yikun ^a   Wang, Xuerong ^a   Yue, Ping ^a   Tao, Hui ^a   Ramalingam, Suresh S ^a   Owonikoko, Taofeek K ^a   Deng, Xingming ^b   Wang, Ya ^b   Fu, Haian ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; DNA; PROTEINS;

AKT PHOSPHORYLATION; ANTICANCER ACTIVITIES; CO INHIBITION; DNA-DEPENDENT PROTEIN KINASE; NOVEL STRATEGIES; PROTEIN PHOSPHATASE 2A; RAPAMYCIN; TARGETED CANCER THERAPY;

PHOSPHORYLATION;

CYCLIN D1; DNA DEPENDENT PROTEIN KINASE; ETOPOSIDE; EVEROLIMUS; FOSTRIECIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; NU 7026; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG; VIRUS SMALL T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84877687558     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.463679     Document Type: Article

References (51)

1. Bjornsti, M. A., and Houghton, P. J. (2004) The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348
2. Guertin, D. A., and Sabatini, D. M. (2005) An expanding role for mTOR in cancer. Trends Mol. Med. 11, 353-361
3. Shaw, R. J., and Cantley, L. C. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430
4. Manning, B. D., and Cantley, L. C. (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 31, 573-578
5. Alessi, D. R., Pearce, L. R., and García-Martínez, J. M. (2009) New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal. 2, pe27
6. Huang, J., and Manning, B. D. (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222
7. Hay, N. (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8, 179-183
8. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
9. Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., and Khuri, F. R. (2005) Activation of Akt and eIF4E survival pathways by rapamycinmediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058
10. O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., Baselga, J., and Rosen, N. (2006) mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508
11. Wang, X., Yue, P., Kim, Y. A., Fu, H., Khuri, F. R., and Sun, S. Y. (2008) Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictorindependent Akt activation. Cancer Res. 68, 7409-7418
12. Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K. A., Sangai, T., Adkins, F., Gonzalez-Angulo, A. M., Rashid, A., Crosby, K., Dong, M., Phan, A. T., Wolff, R. A., Gupta, S., Mills, G. B., and Yao, J. (2012) PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin. Cancer Res. 18, 1777-1789
13. Harrington, L. S., Findlay, G. M., and Lamb, R. F. (2005) Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30, 35-42
14. Manning, B. D. (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167, 399-403
15. Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., Marto, J. A., and Sabatini, D. M. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322
16. Yu, Y., Yoon, S. O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., and Blenis, J. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-1326
17. Westermarck, J., and Hahn, W. C. (2008) Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 14, 152-160
18. Dennis, P. B., Fumagalli, S., and Thomas, G. (1999) Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr. Opin. Genet. Dev. 9, 49-54
19. Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., Kim, Y. W., Liu, J. L., Ramnarian, D., Yuan, Y., Garcia-Echevrria, C., Maira, S. M., and Yung, W. K. (2012) Antitumor activity of NVP-BKM120: a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 18, 184-195
20. Park, E., Park, J., Han, S. W., Im, S. A., Kim, T. Y., Oh, D. Y., and Bang, Y. J. (2012) NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int. J. Oncol. 40, 1259-1266
21. Inuzuka, H., Fukushima, H., Shaik, S., Liu, P., Lau, A. W., and Wei, W. (2011) Mcl-1 ubiquitination and destruction. Oncotarget 2, 239-244
22. Fielhaber, J. A., Han, Y. S., Tan, J., Xing, S., Biggs, C. M., Joung, K. B., and Kristof, A. S. (2009) Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in α4-and protein phosphatase 2A-dependent fashion. J. Biol. Chem. 284, 24341-24353
23. Santhanam, A., Hartley, A., Düvel, K., Broach, J. R., and Garrett, S. (2004) PP2A phosphatase activity is required for stress and Tor kinase regulation of yeast stress response factor Msn2p. Eukaryot. Cell 3, 1261-1271
24. Yorimitsu, T., He, C., Wang, K., and Klionsky, D. J. (2009) Tap42-associated protein phosphatase type 2A negatively regulates induction of autophagy. Autophagy 5, 616-624
25. Hui, L., Rodrik, V., Pielak, R. M., Knirr, S., Zheng, Y., and Foster, D. A. (2005) mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J. Biol. Chem. 280, 35829-35835
26. Weterings, E., and Chen, D. J. (2007) DNA-dependent protein kinase in nonhomologous end joining: a lock with multiple keys? J. Cell Biol. 179, 183-186
27. Hill, R., and Lee, P. W. (2010) The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet? Cell Cycle 9, 3460-3469
28. Chan, D. W., and Lees-Miller, S. P. (1996) The DNA-dependent protein kinase is inactivated by autophosphorylation of the catalytic subunit. J. Biol. Chem. 271, 8936-8941
29. Douglas, P., Moorhead, G. B., Ye, R., and Lees-Miller, S. P. (2001) Protein phosphatases regulate DNA-dependent protein kinase activity. J. Biol. Chem. 276, 18992-18998
30. Wang, Q., Gao, F., Wang, T., Flagg, T., and Deng, X. (2009) A nonhomologous end-joining pathway is required for protein phosphatase 2A promotion of DNA double-strand break repair. Neoplasia 11, 1012-1021
31. Feng, J., Park, J., Cron, P., Hess, D., and Hemmings, B. A. (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 279, 41189-41196
32. Surucu, B., Bozulic, L., Hynx, D., Parcellier, A., and Hemmings, B. A. (2008) In vivo analysis of protein kinase B (PKB)/Akt regulation in DNAPKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J. Biol. Chem. 283, 30025-30033
33. Bozulic, L., Surucu, B., Hynx, D., and Hemmings, B. A. (2008) PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 30, 203-213
34. Boehme, K. A., Kulikov, R., and Blattner, C. (2008) p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc. Natl. Acad. Sci. U.S.A. 105, 7785-7790
35. Dragoi, A. M., Fu, X., Ivanov, S., Zhang, P., Sheng, L., Wu, D., Li, G. C., and Chu, W. M. (2005) DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J. 24, 779-789
36. Park, J., Feng, J., Li, Y., Hammarsten, O., Brazil, D. P., and Hemmings, B. A. (2009) DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif. J. Biol. Chem. 284, 6169-6174
37. Lu, D., Huang, J., and Basu, A. (2006) Protein kinase C∈ activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-α-induced cell death. J. Biol. Chem. 281, 22799-22807
38. Maira, S. M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., Brachmann, S., Fritsch, C., Dorsch, M., Chène, P., Shoemaker, K., De Pover, A., Menezes, D., Martiny-Baron, G., Fabbro, D., Wilson, C. J., Schlegel, R., Hofmann, F., García-Echeverría, C., Sellers, W. R., and Voliva, C. F. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11, 317-328
39. Sun, S. Y., Yue, P., Wu, G. S., El-Deiry, W. S., Shroot, B., Hong, W. K., and Lotan, R. (1999) Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 18, 2357-2365
40. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR com-plex. Science 307, 1098-1101
41. Hresko, R. C., and Mueckler, M. (2005) mTOR-rictor is the Ser-473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416
42. Sun, S. Y., Yue, P., Dawson, M. I., Shroot, B., Michel, S., Lamph, W. W., Heyman, R. A., Teng, M., Chandraratna, R. A., Shudo, K., Hong, W. K., and Lotan, R. (1997) Differential effects of synthetic nuclear retinoid receptorselective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 57, 4931-4939
43. Wang, X., Hawk, N., Yue, P., Kauh, J., Ramalingam, S. S., Fu, H., Khuri, F. R., and Sun, S. Y. (2008) Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther. 7, 1952-1958
44. Bozulic, L., and Hemmings, B. A. (2009) PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr. Opin. Cell Biol. 21, 256-261
45. Huang, S., and Houghton, P. J. (2001) Mechanisms of resistance to rapamycins. Drug Resist. Updat. 4, 378-391
46. Limson, M. V., and Sweder, K. S. (2010) Rapamycin inhibits yeast nucleotide excision repair independently of Tor kinases. Toxicol. Sci. 113, 77-84
47. Chen, H., Ma, Z., Vanderwaal, R. P., Feng, Z., Gonzalez-Suarez, I., Wang, S., Zhang, J., Roti Roti, J. L., and Gonzalo, S. (2011) The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat. Res. 175, 214-224
48. Bandhakavi, S., Kim, Y. M., Ro, S. H., Xie, H., Onsongo, G., Jun, C. B., Kim, D. H., and Griffin, T. J. (2010) Quantitative nuclear proteomics identifies mTOR regulation of DNA damage response. Mol. Cell Proteomics 9, 403-414
49. Huston, E., Lynch, M. J., Mohamed, A., Collins, D. M., Hill, E. V., MacLeod, R., Krause, E., Baillie, G. S., and Houslay, M. D. (2008) EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc. Natl. Acad. Sci. U.S.A. 105, 12791-12796
50. Lucero, H., Gae, D., and Taccioli, G. E. (2003) Novel localization of the DNA-PK complex in lipid rafts: a putative role in the signal transduction pathway of the ionizing radiation response. J. Biol. Chem. 278, 22136-22143
51. Quanz, M., Herbette, A., Sayarath, M., de Koning, L., Dubois, T., Sun, J. S., and Dutreix, M. (2012) Heat shock protein 90α (Hsp90α) is phosphorylated in response to DNA damage and accumulates in repair foci. J. Biol. Chem. 287, 8803-8815